IRCT2017090236033N1 IRCT 2017-10-22 Vice-chancellery for Research of Mashhad University of Medicla Sciences Pathologic response, side-effects, and overall survival in cervical cancer under treatment with neo-adjuvant chemotherapy and surgery Inquiry into pathologic response, complications, and overall survival in patients with locally advanced cervical cancer treated by neo-adjuvant chemotherapy and surgery 2016-12-10 anticipated 30 Complete https://irct.ir/trial/27064 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 locally advanced cervical cancer. Intervention Group: The study has a single group. Pretreatment evaluation includes examination, pelvic magnetic resonance imaging, abdominal sonography, and chest x-ray. Patients receive three one-week periods of neo-adjuvant chemotherapy with paclitaxel (135 milligrams per square meter) on day 1 and cisplatin (75 milligrams per square meter) on day 2 every three weeks for three cycles. Patients without desirable response to chemotherapy will undergo standard pelvic chemoradiotherapy. In case the disease worsens in the 4 to 6 weeks later, the patient will undergo Wertham surgery along with three further chemotherapy cycles. The patients will be candidate for postoperative adjuvant radiation in case they have positive surgical margins, lymph nodes or parametric involvement, or at least two of the following factors: deep stromal invasion, lymphovascular invasion, or size greater than 4 centimeters in the histopathology report of the surgical specimen. Pathologic response of the tumor to treatment will be assessed at the first presentation, after each cycle, and after surgery. Complication of chemoradiotherapy (e.g., nausea, vomit, neutropenia, edema, and neauropathy) will be evaluated after each cycle. Overall survival will be assessed one year after initiation of intervention..